Heart disease in patients with progressive systemic sclerosis may be due in part to myocardial ischemia caused by a disturbance of the coronary microcirculation. To determine whether abnormalities of myocardial perfusion in this disorder are potentially reversible, we evaluated the effect of the coronary vasodilator nifedipine on myocardial perfusion assessed by thallium-201 scanning in 20 patients. Thallium-201 single-photon-emission computerized tomography was performed under control conditions and 90 minutes after 20 mg of oral nifedipine. The mean (+/- SD) number of left ventricular segments with perfusion defects decreased from 5.3 +/- 2.0 to 3.3 +/- 2.2 after nifedipine (P = 0.0003). Perfusion abnormalities were quantified by a perfusion score (0 to 2.0) assigned to each left ventricular segment and by a global perfusion score (0 to 18) for the entire left ventricle. The mean perfusion score in segments with resting defects increased from 0.97 +/- 0.24 to 1.26 +/- 0.44 after nifedipine (P less than 0.00001). The mean global perfusion score increased from 11.2 +/- 1.7 to 12.8 +/- 2.4 after nifedipine (P = 0.003). The global perfusion score increased by at least 2.0 in 10 patients and decreased by at least 2.0 in only 1. These observations reveal short-term improvement in thallium-201 myocardial perfusion with nifedipine in patients with progressive systemic sclerosis. The results are consistent with a potentially reversible abnormality of coronary vasomotion in this disorder, but the long-term therapeutic effects of nifedipine remain to be determined.
This article has been cited by other articles:
Belloli, L., Carlo-Stella, N., Ciocia, G., Chiti, A., Massarotti, M., Marasini, B.
(2008). Myocardial involvement in systemic sclerosis. Rheumatology (Oxford)
47: 1070-1072
[Abstract][Full Text]
Hettema, M. E., Bootsma, H., Kallenberg, C. G. M.
(2008). Macrovascular disease and atherosclerosis in SSc. Rheumatology (Oxford)
47: 578-583
[Abstract][Full Text]
Roman, M. J., Salmon, J. E.
(2007). Cardiovascular Manifestations of Rheumatologic Diseases. Circulation
116: 2346-2355
[Full Text]
Mathai, S. C., Girgis, R. E., Fisher, M. R., Champion, H. C., Housten-Harris, T., Zaiman, A., Hassoun, P. M.
(2007). Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J
29: 469-475
[Abstract][Full Text]
Kahan, A., Allanore, Y.
(2006). Primary myocardial involvement in systemic sclerosis. Rheumatology (Oxford)
45: iv14-iv17
[Abstract][Full Text]
Meune, C., Allanore, Y.
(2006). Abnormal right ventricular diastolic function may not be the only early marker of myocardial involvement in systemic sclerosis.. Chest
130: 302-302
[Full Text]
Meune, C., Allanore, Y., Pascal, O., Devaux, J.-Y., Dessault, O., Duboc, D., Weber, S., Kahan, A.
(2005). Myocardial contractility is early affected in systemic sclerosis: A Tissue Doppler echocardiography study. Eur J Echocardiogr
6: 351-357
[Abstract][Full Text]
Vignaux, O, Allanore, Y, Meune, C, Pascal, O, Duboc, D, Weber, S, Legmann, P, Kahan, A
(2005). Evaluation of the effect of nifedipine upon myocardial perfusion and contractility using cardiac magnetic resonance imaging and tissue Doppler echocardiography in systemic sclerosis. Ann Rheum Dis
64: 1268-1273
[Abstract][Full Text]
Borderie, D., Allanore, Y., Meune, C., Devaux, J. Y., Ekindjian, O. G., Kahan, A.
(2004). High Ischemia-Modified Albumin Concentration Reflects Oxidative Stress But Not Myocardial Involvement in Systemic Sclerosis. Clin. Chem.
50: 2190-2193
[Full Text]
Montisci, R, Vacca, A, Garau, P, Colonna, P, Ruscazio, M, Passiu, G, Iliceto, S, Mathieu, A
(2003). Detection of early impairment of coronary flow reserve in patients with systemic sclerosis. Ann Rheum Dis
62: 890-893
[Abstract][Full Text]
Kawut, S. M., Taichman, D. B., Archer-Chicko, C. L., Palevsky, H. I., Kimmel, S. E.
(2003). Hemodynamics and Survival in Patients With Pulmonary Arterial Hypertension Related to Systemic Sclerosis. Chest
123: 344-350
[Abstract][Full Text]
Geirsson, A J, Wollheim, F A, Akesson, A
(2001). Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale. Ann Rheum Dis
60: 1117-1122
[Abstract][Full Text]
Nakajima, K., Taki, J., Kawano, M., Higuchi, T., Sato, S., Nishijima, C., Takehara, K., Tonami, N.
(2001). Diastolic Dysfunction in Patients with Systemic Sclerosis Detected by Gated Myocardial Perfusion SPECT: An Early Sign of Cardiac Involvement. JNM
42: 183-188
[Abstract][Full Text]
Liangos, O., Neure, L., Kuhl, U., Pauschinger, M., Sieper, J., Distler, A., Schwimmbeck, P. L., Braun, J.
(2000). The possible role of myocardial biopsy in systemic sclerosis. Rheumatology (Oxford)
39: 674-679
[Abstract][Full Text]
Sarda, L, Assayag, P, Palazzo, E, Vilain, D, Guillevin, L, Faraggi, M, Meyer, O, Le Guludec, D
(1999). 111Indium antimyosin antibody imaging of primary myocardial invovement in systemic diseases. Ann Rheum Dis
58: 90-95
[Abstract][Full Text]
Rinaldi, E., Ierardi, M., Tiberio, N.S., Boccabella, G. L., Barbieri, C., Scopinaro, F., Morelli, S., DeSantis, M., Banci, M.
(1998). 99mTc SESTAMIBI Scintigraphic Evaluation of Skeletal Muscle Disease in Patients with Systemic Sclerosis: Diagnostic Reliability and Comparison with Cardiac Function and Perfusion. ANGIOLOGY
49: 641-648
[Abstract]
Ferri, C., Di Bello, V., Martini, A., Giorgi, D., Storino, F. A A, Bianchi, M., Bertini, A., Paterni, M., Giusti, C., Pasero, G.
(1998). Heart involvement in systemic sclerosis: an ultrasonic tissue characterisation study. Ann Rheum Dis
57: 296-302
[Abstract][Full Text]
Belch, J.
(1997). Raynaud's phenomenon. Cardiovasc Res
33: 25-30
[Full Text]
